Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Vollmer

Interventional Pain Medicine Saint Marys, PA Doctor of Osteopathy

NPI 1851644637 CMS profile 1156433

1095 Million Dollar Hwy # A, Saint Marys, PA 15857

Open in the dashboard

General payments

$4,454

72 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Vollmer of Saint Marys, PA is reported in the CMS Open Payments database as having received $4,454 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,514 13
2024 General $285 12
2023 General $135 5
2022 General $95 4
2021 General $471 10
2020 General $1,638 18
2019 General $317 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Vollmer
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Timothy Vollmer were reported at $1,514. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Timothy Vollmer Interventional Pain Medicine median Middle half National median
2019 $317 $684 $216–$2,079 $163
2020 $1,638 $382 $122–$1,109 $114
2021 $471 $552 $167–$1,554 $132
2022 $95 $605 $187–$1,924 $149
2023 $135 $671 $195–$1,915 $160
2024 $285 $684 $206–$1,837 $164
2025 $1,514 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,018 43 payments
  2. SI-BONE, Inc. $1,262 10 payments
  3. Pacira Pharmaceuticals Incorporated $741 4 payments
  4. Boston Scientific Corporation $138 5 payments
  5. Medtronic, Inc. $133 3 payments
  6. Bioventus LLC $96 4 payments
  7. Amgen Inc. $39 1 payment
  8. Flexion Therapeutics, Inc. $16 1 payment
  9. Foundation Fusion Solutions, LLC $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,731 66 payments
  2. Travel and Lodging $1,723 6 payments
Products named General payments · program years 2019–2025
  1. IFUSE IMPLANT SYSTEM $1,170 6 payments
  2. Proclaim Family of SCS IPGs $904 16 payments
  3. iovera System $338 1 payment
  4. EXPAREL $328 1 payment
  5. Proclaim IPG $196 3 payments
  6. Octrode SCS Leads $174 4 payments
  7. PROCLAIM $147 1 payment
  8. KYPHON Balloon Kyphoplasty $100 1 payment
  9. ETERNA Structural Heart $91 1 payment
  10. ETERNA Neuromodulation $89 2 payments
  11. Other $778 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

724

Median for Anesthesiology: 322

Drug cost

$7,666

Median for Anesthesiology: $8,738

Branded share of claims

23.3%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 207 $3,519
Duloxetine Hcl Generic 50 $1,009
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 50 $837
Nortriptyline Hcl Generic 24 $584
Celecoxib Generic 15 $354
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 119 $336
Tramadol Hcl Generic 48 $297
Mupirocin Generic 23 $193
Meloxicam Generic 29 $182
Pregabalin Generic 13 $152

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$777,881

Of which drugs: $19,854

Medicare patients

870

Average age 75

Services billed

50,220

501 women, 369 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 30%
Osteoporosis 28%
Ischemic heart disease 27%
Depression 26%
Chronic kidney disease 24%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 55 207 $11,779
Injection, methylprednisolone acetate, 1 mg J1010 Office 299 35,846 $3,617
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 423 3,482 $2,625
Injection, methylprednisolone acetate, 80 mg J1040 Office 111 112 $850
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 668 2,189 $621
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 212 3,224 $288
Injection, cefazolin sodium, 500 mg J0690 Office 26 79 $48

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record